Variants of Hepatitis B Virus Resistant Against Some Nucleoside Analogues, but Sensitive to Others, and Uses Thereof

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses and characterizes specific variants of the hepatitis B virus (HBV) that have developed resistance to some nucleoside analogue antiviral drugs, such as lamivudine and adefovir, but remain sensitive to others, notably tenofovir. The invention also provides assays, diagnostic kits, and methods to detect these resistant HBV variants in biological samples and recommends personalized treatment strategies based on the resistance profile. Furthermore, the invention enables the screening for new drugs effective against these resistant variants.

Use CasesContent extracted from patent full text and abstract with AI.

• Personalized management of hepatitis B treatment by identifying resistant HBV strains and guiding selection of the most effective antiviral drugs.
• Routine clinical monitoring of HBV-infected patients to detect emerging drug resistance and adapt treatment promptly.
• Development and commercialization of diagnostic kits for resistance testing in clinical laboratories.
• Screening and discovery of new antiviral drugs that are effective against drug-resistant HBV.
• Basic and clinical research into HBV resistance mechanisms and antiviral drug efficacy.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables tailored hepatitis B therapy by identifying which drugs a patient's HBV variant is resistant or sensitive to, improving treatment success rates.
• Reduces trial-and-error in HBV drug therapy, minimizing unnecessary exposure to ineffective drugs and potential side effects.
• Accelerates detection of emerging HBV resistance, allowing for timely intervention and better disease control.
• Supports development of more effective drugs and diagnostics, advancing public health outcomes.
• Applicable to both clinical care settings and pharmaceutical research, offering flexibility and wide utility.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates generally to the field of Hepatitis B variants exhibiting a reduced sensitivity to nucleoside analogues both in vivo and in vitro. More in particular, reverse transcriptase mutant rt 1233 V is provided. Present invention provides assays and methods for detecting such variant, which assays are useful in monitoring anti- viral therapeutic regimes and adjusting patient therapy. A diagnostic kit for detecting the presence of an HBV variant in a biological sample has also been described. Finally, the use of a farmaceutical composition to cure a subject suffering from a HBV infection, which HBV is resistant to lamuvidine and/or adefovir has been provided, which farmaceutical composition comprises the nucleoside analogue tenofovir.